 |
|
|
|
|
PI3K Pathway: PI3K
 | | |  PI3K Antibodies
|
|
|
|
|
| Anti-PI 3-K Mouse mAb (AB6) Mouse mAb (AB6) |
IB, IC, IP |
human, mouse, rat |
528107 |
| Anti-PI 3-K p110d, C-Terminal (1026-1044) Rabbit pAb |
IB, IC |
human |
526553 |
|
| | | PI3K Inhibitors
| | | PI3K Proteins/Enzymes
|
|
|
| PI 3-K, His•Tag®, Human, Recombinant, E. coli |
526555 |
| PI 3-Kb, p110b/p85a, Human, Recombinant, S. frugiperda |
526554 |
| PI 3-Kd, p110d/p85a, GST-Fusion, Human, Recombinant, S. frugiperda |
526558 |
| PI 3-Kg, His•Tag®, Human, Recombinant, S. frugiperda |
526556 |
|
| | | | Additional Information | | | | | | | | |
| Protein : PIK3CA
| | |
|---|
| Name | PIK3CA |
|---|
| Description | phosphoinositide-3-kinase, catalytic, alpha polypeptide |
|---|
| Owner | Public |
|---|
| URN | urn:agi-llid:5290 |
|---|
| Connectivity | 32 |
|---|
| Notes | Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. Amino acid substitutions in PIK3CA from human colorectal cancer cell lines constitutively activate the AKT pathway, and consequently, promote tumor cell growth and invasion. Colon cancer-associated PIK3CA mutations are functionally active so that they are likely to be involved in carcinogenesis. Data indicate that mutations of PIK3CA play an oncogenic role in substantial fractions of ovarian and breast carcinomas. Data show that glucose is a crucial regulator of V-ATPase in renal epithelial cells and that the effect of glucose is mediated by phosphatidylinositol 3-kinase (PI3K). Genetic alterations of class IA PI3K subunit genes can occasionally play a role in human glioblastoma by activating the PI3K-AKT signaling pathway independently of PTEN mutation. In squamous cell carcinomas the negative effect of p53 induction on cell survival involves transcriptional inhibition of PIK3CA that is independent of PTEN activity, as PTEN is not expressed in the primary tumors. Missense Mutation in PIK3CA is associated with breast cancers. Mutation of PIK3CA is frequent, occurs early in carcinoma development, and has prognostic and therapeutic implications for breast cancer. Mutations of PIK3CA is associated with anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. This paper reports the first purification of a phosphoinositide 3-kinase and shows that the protein is a heterodimer of an 85 kd regulatory subunit that mediates binding to phosphorylated proteins and a 110 kd catalytic subunit. Agonist binding to Gq-coupled receptors blocks Akt activation via the release of active Galphaq subunits that inhibit PI3K via an inhibitory interaction between Galphaq and p110alpha PI3K. Data suggest that mutant PIK3CA is likely to function as an oncogene in human cancers; PIK3CA may prove useful for diagnostic and therapeutic purposes. Determined the growth-regulatory and signaling properties of the three most frequently observed PIK3CA mutations: E542K, E545K, and H1047R. Mutation of the PIK3CA gene is not common, but its amplification is relatively common and may be a novel mechanism in activating the PI3K/Akt pathway in some thyroid tumors. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform. |
|---|
| Hugo ID | 8975 |
|---|
| | |
|---|
| Microarray ID | 92452_at |
|---|
| | msa.241.0_at |
|---|
| | msa.241.0_g_at |
|---|
| | A_51_P166682 |
|---|
| | A_52_P265002 |
|---|
| | 40704_at |
|---|
| | 204369_at |
|---|
| | Z29090_at |
|---|
| | A_23_P92057 |
|---|
| | A_14_P108238 |
|---|
| | A_14_P128410 |
|---|
| | A_14_P113684 |
|---|
| | A_14_P127878 |
|---|
| | M186 |
|---|
| | 777 |
|---|
| | OH7894 |
|---|
| | |
|---|
| Chromosome position | 2q25 |
|---|
| | 3 12.4 cM |
|---|
| | 3q26.3 |
|---|
| | |
|---|
| GO ID | 0016301 |
|---|
| | 0016773 |
|---|
| | 0030027 |
|---|
| | 0043066 |
|---|
| | 0004428 |
|---|
| | 0005515 |
|---|
| | 0005942 |
|---|
| | 0007165 |
|---|
| | 0016303 |
|---|
| | 0016740 |
|---|
| | 0046934 |
|---|
| | 0006468 |
|---|
| | 0006916 |
|---|
| | |
|---|
| Alias | caPI3K |
|---|
| | P110-ALPHA |
|---|
| | phosphatidylinositol 3-kinase, catalytic, alpha polypeptide |
|---|
| | PI3K P110-ALPHA |
|---|
| | PI3K-ALPHA |
|---|
| | PIK3CA |
|---|
| | RIKEN cDNA 6330412C24 gene |
|---|
| | Phosphatidylinositol 3-kinase catalytic subunit, alpha isoform |
|---|
| | 6330412C24Rik |
|---|
| | hydroxykinase |
|---|
| | hydroxykinases |
|---|
| | phosphoinositide-3-kinase, catalytic, alpha polypeptide |
|---|
| | PI3-kinase P110 subunit alpha |
|---|
| | |
|---|
| Organism | Rattus norvegicus |
|---|
| | Homo sapiens |
|---|
| | Mus musculus |
|---|
| | |
|---|
| FunctionalClass | kinase |
|---|
| | phosphotransferase activity, alcohol group as acceptor |
|---|
| | phosphatidylinositol 3-kinase |
|---|
| | phosphatidylinositol-4,5-bisphosphate 3-kinase |
|---|
| | protein binding |
|---|
| | transferase |
|---|
| | inositol or phosphatidylinositol kinase |
|---|
| | |
|---|
| GO Cellular Component | phosphoinositide 3-kinase complex |
|---|
| | lamellipodium |
|---|
| | |
|---|
| Cell Localization | Cytoplasm |
|---|
| | |
|---|
| Pathway | AGT-LRP2 |
|---|
| | EGF-ERBB3 |
|---|
| | F2-ITGAV |
|---|
| | F2-LRP1 |
|---|
| | F2-LRP2 |
|---|
| | F2-THBD |
|---|
| | IGF1-BST1 |
|---|
| | IGF1-IGF2R |
|---|
| | IGF1-LRP5 |
|---|
| | INS-EGFR |
|---|
| | INS-HLA-DRB1 |
|---|
| | INS-TFRC |
|---|
| | VEGF-CD44 |
|---|
| | VEGF-EGFR |
|---|
| | VEGF-GPC1 |
|---|
| | VEGF-IL1R1 |
|---|
| | CB0480 Insulin |
|---|
| | simple mTOR |
|---|
| | |
|---|
| GO Biological Process | signal transduction |
|---|
| | anti-apoptosis |
|---|
| | negative regulation of apoptosis |
|---|
| | protein amino acid phosphorylation |
|---|
|
|
 |
|
|
